Skip to main content
main-content

Bone diseases

Medications

07-11-2019 | Osteoporosis | News

Unfavorable risk–benefit profile of odanacatib for osteoporosis treatment

The cathepsin K inhibitor odanacatib reduces the incidence of fracture in postmenopausal women with osteoporosis, but at the cost of an increased risk for cardiovascular events, indicate findings from the LOFT trial.

09-09-2019 | Osteoporosis | News

Denosumab plus high-dose teriparatide may improve postmenopausal osteoporosis

Combining denosumab with high-dose rather than standard-dose teriparatide results in greater increases in spine and hip bone mineral density in postmenopausal women with osteoporosis, phase IV study data show.

Meta-analysis questions use of osteoporosis treatments to reduce mortality risk

Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.

27-08-2019 | Osteoporosis | News | Article

Meta-analysis questions use of osteoporosis treatments to reduce mortality risk

Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.

10-07-2019 | Psoriatic arthritis | News

Biologic treatment may improve control of PsA-related bone disease

Psoriatic arthritis patients treated with biologic DMARDs have higher bone mass and strength than those not receiving DMARD treatment, suggest findings from a cross-sectional study.

03-06-2019 | Rheumatoid arthritis | Highlight | News

IL-6 receptor inhibition may induce bone erosion repair in RA

Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.

IL-6 receptor inhibition may induce bone erosion repair in RA

Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

24-05-2019 | Rheumatoid arthritis | Highlight | News

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

25-04-2019 | Osteoporosis | News

No difference in fracture risk with denosumab vs alendronate

Patients initiating denosumab have a similar 3-year fracture risk to those initiating alendronate, regardless of sex, age, or fracture history, show results of a large study among Danish patients in routine clinical practice.

24-04-2019 | Osteoporosis | Highlight | News

Long-term drug treatment may reduce fracture risk in women with osteoporosis

Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.

Long-term drug treatment may reduce fracture risk in women with osteoporosis

Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.

11-04-2019 | Osteoporosis | News

FDA approves romosozumab for fracture prevention in osteoporosis

Click through for more information on this announcement

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

27-10-2018 | Denosumab | ACR/ARHP 2018 | Video

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

24-10-2018 | Osteoporosis | ACR/ARHP 2018 | News

Two-year data support denosumab use in patients with glucocorticoid-induced osteoporosis

Greater increases in bone mineral density seen with denosumab versus risedronate in glucocorticoid-treated patients with osteoporosis are sustained through 24 months, indicate phase III data.

No benefit of vitamin D supplementation for musculoskeletal health

The use of vitamin D supplements for maintaining or improving musculoskeletal health is not warranted, suggest the findings of an updated systematic review and meta-analysis.

Image Credits